Is Regeneron Stock a Buy After a Regulatory Blow?
Don't write this company's eulogy too fast.
Source: fool.com
📰 While Regeneron News
While Regeneron News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from While Regeneron. Real-time updates on events, politics, business and more.
PTAB to Review Two Eylea® (aflibercept) Patents After Granting Mylan's Challenges | Rothwell, Figg, Ernst & Manbeck, P.C.
The U.S. Patent and Trademark Office (USPTO) recently instituted two of Mylan’s petitions seeking Inter Partes Review of Regeneron’s U.S. Patent No. 9,669,069 B2 (the “’069 Patent,”...
Source: jdsupra.com